About

Morad Amadji, President

Morad is a Doctor Es Sciences in Chemistry by education, he has an extensive scientific, operational, and managerial experience in the pharmaceutical industry covering development, manufacturing as well as supplier management for pharmaceuticals, vaccines, and biotech products. He has more than 25 years of experiences in various pharma Co mainly in 3 areas; 8 years in R&D including molecules synthesis and safety process, 8 years in Analytical Development & Quality Control and 8 years in Quality Assurance Specialist.

Certified GMP and API Auditor, Morad participated in several GMP and for cause audits as well as interacted with FDA, ANSM and other health authorities during inspections. In his current position, he leads and manages the team of corporate quality auditors for ensuring an efficient quality management of suppliers and contractors used for manufacturing Sanofi products and materials.

Shine Gao, Vice President

Shine Graduated from China Pharmaceutical University in 2010, majoring in Pharmaceutical Analysis, with 8 years of quality management experience in drug manufacturing company. Familiar with pharmaceutical GMP quality management system, like change control, deviation investigation, CAPA system, supplier management etc.

From 2018 to now, Shine worked in pharmaceutical excipient industry, mainly responsible for China CDE registration, quality, and technical support. Familiar with excipient GDP regulations,  she has established and maintained a set of quality management systems for distributors. In her spare time, she also serves as the Chairman of the IPEC China Quality Sub-Committee and as a technical expert on excipient GMP for DQS, a third-party certification body.

Anne-Catherine Bildstein, Treasurer

With over 30 years of experience in the life science industry, Anne-Catherine has developed strong experience in quality and compliance and more specifically in the auditing area. She started working on quality audits while she was at Lilly’s parenteral manufacturing site in France, conducting internal audits. Subsequently at Novartis, she was responsible for the GxP audit plan for the group; during that time, she led a cross company GxP audit improvement project to harmonize and standardize the end-to-end audit process. In her current role as VP QMS and Compliance at Ipsen she is responsible for the global GxP audit team, driving transformation within this landscape to enhance and optimize the process.

Jessica Nicole Cansler, Board Member

Jessica holds a master’s in jurisprudence in Health Law from Seton Hall University and B.S. in Biomedical Engineering from Rutgers University. She has held various roles in Quality and Engineering within the Pharma and Biologics industries. She started her career at BASF in Sep 2011 as Quality Management Specialist for the North America region, gaining experiences in various quality realms and represented BASF’s Quality interests in various trade organizations (i.e., IPEC Americas, ASQ, etc.)

Jessica is now a Quality Compliance Manager for BASF Global Quality Governance. She is an America Society of Quality (ASQ) Certified Quality Auditor. As a member of IPEC America, she functions as the lead for the Education Strategy team and serve as an active contributing member for the GMP, Excipient Qualification, and QbD committees

Ravleen Singh Khurana, Board Member

Ravleen Singh Khurana is the Secretary of IPEC India and brings over 34 years of extensive experience in the pharmaceutical industry. He is also an entrepreneur par excellence. Mr Khurana, has done his Masters in Pharmaceutical Technology from Nagpur University in 1994 followed by MBA in Marketing. Under his leadership, Nitika Pharma has achieved many milestones and prestigious awards in the industry.

He founded Nitika Pharmaceuticals Specialties Pvt Ltd in 1991, at the age of 19. Today Nitika Pharma is the world's leading excipients manufacturer, exporting to the MNCs and pharma giants in 90 countries across the globe. Awarded By INDIAN PHARMA Award 2024 in category of Excellence in Make In India and Having Largest MCC Plant In Asia world in Nov 2024. Founded in 1991 by Ravleen Singh Khurana, the company has grown significantly to achieve global recognition, with exports to over 90 countries worldwide.

Ian Patrick McKeown, Board Member

In continuing to support EXCiPACT in the preparation and update of the EXCiPACT Standard, and with IPEC in the preparation of the IPEC PQG GMP Guide, Ian is highly motivated to join EXCiPACT’s management body in order to assist in the continued growth of the organisation. He is also passionate about assuring patient safety through best practice in the manufacture and distribution of excipients. Sitting on the PQG committee he is keen to maintain liaison between this group and EXCiPACT.

Kaushik Desai, Board Member

A post graduate in Pharmaceutical Technology with Industrial Management diploma, Mr. Desai has a career spanning over 35 years of multifunctional experience in various leadership roles with reputed pharmaceutical companies, Sanofi, Pfizer, Johnson & Johnson, Charak Pharma and Global Pharmatech (Maiva). Mr. Desai’s areas of expertise include management of both green and brown field projects, technology transfer, plant operations, contract manufacturing, Quality Systems, regulatory intelligence, and business development.

At International Pharmaceutical Federation (FIP), Mr. Desai is Executive Committee member of the Industrial Pharmacy section and Editorial Advisory Board member of International Pharmacy Journal. He is also past Section Chair of Industrial Pharmacy & Marketing section with Federation of Asian Pharmaceutical Associations (FAPA) and Director of DIA India. He has been in the leadership team of Indian Pharmaceutical Association as Vice President, Chairman - Industrial Pharmacy Division, National General Secretary, Hon. Treasurer and Editor - Pharma Times in addition to playing an active role in organizing number of national scientific conferences, conventions, technical trainings, and exhibitions.

Iain Moore, Senior Advisor

Iain was Global Head of Quality Assurance Croda Europe Ltd, a manufacturer of speciality and performance chemicals based in the United Kingdom. He  worked for Croda for 36 years, and for more than 25 years in various quality roles, including overseeing two UK regulatory inspections.  He has contributed to the publication of European and US National Standards as well as many IPEC Guides. He was project leader for the development and delivery of the EXCiPACT Certification Scheme, and stood as its first President, and has latterly returned to the Board as President and Chairman of the Board succeeding Kevin McGlue from 2016 to 2022. He is also  chair of the EFFCI (European Federation for Cosmetic Ingredients) GMP Committee which oversees the EFfCI GMP Guide and standard for cosmetic Ingredients.

Alain Becart, Quality Manager

Alain has a Doctorate in Industrial Pharmacy and a Masters degree in Analytical Chemistry and Quality Control. He started his career as Head of Quality Control in Pharmaceutical Manufacturing with the French offices of Ethypharm and Boehringer Ingelheim. In 1995, he joined Rhone Poulenc Rorer (a Sanofi legacy company) in their R&D – Analytical Sciences department with responsibility for clinical batches analysis and stability testing.

In 2005, he became responsible for Suppliers Quality Management worldwide within the Industrial Quality & Compliance corporate department Sanofi-Aventis, where he built a global system to manage the quality of third parties, including audits of manufacturers and distributors of pharmaceutical starting materials. He retired in October 2017 as Director Quality of Third Parties in SANOFI Global Quality based in Paris.

Since 2010, Alain has been President of the Pharmaceutical Starting Material Forum within the Quality Group of the LEEM - the professional organisation of pharmaceutical companies operating in France. In January, 2017, he became the Quality Manager of EXCiPACT asbl with responsibility for the approval of their Registered Certification Bodies and Registered Auditors, and for ensuring compliance of EXCiPACT certification actions with regards to ISO 19011 and ISO 17021 standards.